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Abstract
Background: RhoH is a constitutively active member of the family of Rho GTPases. Its expression is restricted to
the haematopoietic lineage, where it serves as a positive regulator for T cell selection and mast cell function and
as a negative regulator for growth-related functions in other lineages. Here, we examined the activation of signal
transducer and activator of transcription (STAT) proteins in response to stimulation with interleukin 3 (IL3).
Results: Using the murine IL3-dependent cell line BaF3 we investigated the influence of RhoH protein expression
levels on IL3-mediated cellular responses. RhoH overexpressing cells showed lower sensitivity to IL3 and decreased
STAT5 activation. SiRNA-mediated repression of RhoH gene expression led to an increase in proliferation and STAT5
activity which correlated with an increased number of IL3 receptor a chain molecules, also known as CD123,
expressed at the cell surface. Interestingly, these findings could be reproduced using human THP-1 cells as a
model system for acute myeloid leukaemia, where low RhoH levels are known to be an unfavourable prognostic
marker. Overexpression of RhoH on the other hand caused an induction of STAT1 activity and western blot analysis
revealed that activated STAT1 is phosphorylated on Tyr701. STAT1 is known to induce apoptosis or cell cycle arrest
and we detected an upregulation of cyclin-dependent kinase inhibitors (CDKI) p21Cip1 and p27Kip1 in RhoH
overexpressing BaF3 cells.
Conclusions: We propose that RhoH functions as a negative regulator for IL3-induced signals through modulation
of the JAK-STAT pathway. High levels of RhoH allow the IL3-dependent activation of STAT1 causing decreased
proliferation through upregulation of p21Cip1 and p27Kip1. Low RhoH levels on the other hand led to an
upregulation of IL3-dependent cell growth, STAT5 activity and an increase of CD123 surface expression, linking
RhoH to a CD123/STAT5 phenotype that has been described in AML patients.
Background
Rho GTPases belong to the superfamily of Ras GTPases
[1] and function as molecular switches that control and
integrate signal transduction pathways by linking recep-
tor-derived signals to downstream signalling proteins
[2-4]. The Rho subfamily of GTPases consists of 20 pro-
teins, but only two members, Rac2 and RhoH, are speci-
fically expressed in haematopoietic cells [5,6]. RhoH is a
GTPase deficient protein [7,8] and its activity is presum-
ably modulated through transcriptional regulation [7].
Recently it was found that RhoH activity can also be
regulated by tyrosine phosphorylation of its non-canoni-
cal immune receptor tyrosine activation motif (ITAM)
[9]. The protein was first discovered as a fusion tran-
script with the transcriptional repressor LAZ3/BCL6 in
Non Hodgkin lymphoma cells [5]. In a number of B cell
malignancies, RhoH is mutated with high frequency
through somatic hypermutation [10,11]. In Hairy Cell
Leukaemia (HCL) and Acute Myeloid Leukaemia
(AML), RhoH was found to be underexpressed at the
protein level [12,13]. The function of RhoH has been
investigated in various haematopoietic cells and RhoH is
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thought to mainly act as a negative regulator for pro-
cesses such as proliferation, survival, migration and
engraftment of haematopoietic progenitor cells [14].
This is presumably due to the negative regulatory role
RhoH has on Rac1 [7,13,15], although the exact
mechanism remains to be elucidated. RhoH null mice
showed impaired T cell differentiation due to defective
T cell receptor signalling [9,16]. However, other func-
tions of RhoH have now become known that had not
been obvious from the knock-out animals [17-19]. In
mast cells, for example, RhoH positively regulates signal-
ling through the FcεR [18]. In neutrophils from patients
suffering from chronic obstructive pulmonary disease
[19] or cystic fibrosis [17], a GM-CSF-dependent upre-
gulation of RhoH had been found. These data were cor-
roborated using RhoH-deficient mice, showing that
RhoH negatively regulates leukotriene production.
Here, we demonstrate that RhoH regulates interleukin
3 (IL3)-induced signalling through modulation of the
activity of signal transducer and activator of transcrip-
tion (STAT) proteins. Important functions of IL3 are
the regulation of growth and early differentiation of hae-
matopoietic progenitors [20] as well as the control of
the terminal differentiation of basophils, mast cells and
dendritic cells [21,22]. Recent publications suggest a
strong link between RhoH expression levels and B cell
malignancies [12,13]. We therefore used IL3-dependent
BaF3 cells, a murine proB cell line, as a model system.
These cells were shown to express comparatively low
levels of RhoH [7]. We show that overexpression of
RhoH decreases IL3-induced proliferation and the activ-
ity of STAT5. The surface expression level of the IL3
receptor a-chain (CD123) is inversely correlated to the
expression levels of RhoH. In RhoH-deficient cells, the
STAT5-dependent gene interferon regulatory factor-1
(IRF-1) is upregulated, eventually leading to an upregu-
lation of CD123. Interestingly, only BaF3 cells that over-
express RhoH are able to activate STAT1 after
stimulation with IL3. This correlates with an upregula-
tion of the STAT1-dependent cell cycle inhibitors
p21Cip1 and p27Kip1. Thus, our findings link the regula-
tory function of RhoH on proliferation to an interaction
with the JAK-STAT signalling pathway.
Results
RhoH regulates IL3-dependent cell proliferation
In order to study the effects of RhoH on IL3-mediated
signals, we used the IL3-dependent, murine proB cell
line BaF3 to generate cell lines where the RhoH gene
was silenced (siRhoH) using the retroviral vector pSilen-
cer Retro 5.1 U6 (Ambion, Austin, USA) or that were
retrovirally transduced with RhoH to overexpress the
protein (RhoH). As a control, parental BaF3 cells were
transduced with the empty vector (pMX-IRES-CD4-
Puro). Infected cells were selected with puromycin and
the resulting stable cell lines were tested for RhoH
expression by quantitative real-time PCR using GAPDH
as a reference gene. Figure 1 A shows that in siRhoH
cells the expression was decreased to app. 10% com-
pared to control cells, while the RhoH cells showed a
five-fold overexpression of the gene. To corroborate
successful retroviral transduction, we performed FACS
analysis and compared CD4 expression levels. It was
shown previously that the level of expression of the
genes up- and downstream of the IRES sequence are
highly correlated in stably infected target cells [23].
Figure 1B shows that control cells and RhoH-transduced
cells were app. 80% positive for CD4 expression and
expressed the vector at comparable levels. Parental cells
that do not express CD4 were used as a negative
control.
To investigate whether the overexpression of RhoH
leads to changes in IL3 receptor-mediated signalling
events, proliferative responses were tested using control
cells and BaF3 cells overexpressing RhoH (Figure 1C).
Cells were incubated with IL3 concentrations ranging
from 0.001 to 1 ng/ml and factor-dependent growth was
determined after 48 hours through measurement of cel-
lular ATP (Cell Titer Glo, Promega). In RhoH cells, the
ability to proliferate in response to IL3 was reduced to
app. 30%. On the other hand, siRhoH cells proliferated
better in response to IL3 achieving a growth rate of 160%
compared to cells transduced with the empty vector.
Thus, the expression level of RhoH regulates the ability
of BaF3 cells to proliferate in response to IL3. To clarify
whether these findings were specific for IL3, we repeated
the experiment with BaF3 cells transduced with erythro-
poietin receptor (EpoR). EpoR cells, EpoR-RhoH cells
and parental BaF3 cells were cultivated at Epo concentra-
tions between 0.01 and 6.5 U/ml and cell viability was
again determined after 48 h (Figure 1D). Interestingly, no
differences in Epo-induced growth could be detected
between EpoR and EpoR-RhoH cells. Parental BaF3 cells
were not able to grow, as expected, since they do not
express the EpoR. We therefore conclude that RhoH spe-
cifically regulates IL3-induced proliferation.
RhoH modulates IL3-induced STAT activation
Next, we investigated if the changes in cell proliferation
were related to changes in the transduction of IL3-
induced signals. STAT proteins are cytokine inducible
transcription factors that act as regulators of prolifera-
tion and apoptosis. It was shown that overexpression of
RhoH leads to a decrease in proliferation in murine hae-
matopoietic progenitor cells that could be explained by
an increased number of apoptotic cells [14]. In these
studies, no signalling cascade was identified that could
be responsible for a proapoptotic function of RhoH.
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Figure 1 RhoH regulates IL3-induced proliferation. (A) RhoH mRNA expression levels in control cells, RhoH or siRhoH-transduced BaF3 cells
were detected by quantitative real-time PCR using RhoH specific primers and GAPDH as a reference gene. Statistical significance was analysed
using the ‘s t-test (mean ± SD, n = 2 and *P ≤ 0.05; **P ≤ 0.01). (B) FACS analysis of control cells transduced with the empty vector (pMX-IRES-
CD4-Puro) or RhoH (pMX-IRES-CD4-Puro RhoH) -transduced BaF3 cells for human CD4 expression after puromycin selection. Parental BaF3 cells
were used as a negative control. (C) Dose response curve of control cells, RhoH and siRhoH BaF3 cells cultivated with increasing concentrations
of IL3. Viability was determined by quantification of cellular ATP in a Cell Titer Glo assay. Results shown are from one representative experiment
performed in triplicates ± SD. (D) Dose response curve of BaF3 cells, BaF3-EpoR cells and BaF3-EpoR cells overexpressing RhoH cultivated with
increasing concentrations of Epo. Viability was determined by quantification of cellular ATP in a Cell Titer Glo assay. Results shown are from one
representative experiment performed in triplicates ± SD.
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Figure 2 RhoH expression triggers IL3-dependent STAT1 activation. (A) Control cells, siRhoH and RhoH-transduced BaF3 cells were depleted
of cytokine and FBS for 3 h prior to stimulation with IL3. Phosphorylated STAT1 levels were measured with intracellular FACS staining using a
FITC-labelled pTyr-STAT1 specific antibody. One representative result of three independent experiments is shown. (B) Control and RhoH cells
were starved for 3 hours prior to stimulation with 50 ng/ml IL3. Cells were lysed, STAT1 was immunoprecipitated and tyrosine phosphorylated
STAT1 and total STAT1 were detected by enhanced chemiluminescence. Quantification of pSTAT1 levels was done after normalisation to STAT1
levels in cells transduced with the empty vector and is presented as induction of phosphorylation compared to the corresponding unstimulated
sample. Statistical significance was analysed using the ‘s t-test (mean ± SD, n = 3; ***P ≤ 0.005). (D) Apoptosis was induced in control cells,
siRhoH or RhoH-transduced cells by cultivation in the absence of IL3 (overnight), treatment with 1 μM staurosporine (3 h) or with 1 μM
doxorubicine (12 h) prior to Annexin V/PI staining and FACS analysis (mean ± SD, n = 3).
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Thus we examined whether the activity of STAT1 which
is known to activate proapoptotic pathways, is modu-
lated by the expression level of RhoH. We therefore sti-
mulated control cells, siRhoH and RhoH cells for 10
min with 50 ng/ml IL3 and measured the phosphoryla-
tion status by intracellular FACS analysis (Figure 2A).
The data show that there is no significant tyrosine phos-
phorylation detectable in vector transduced BaF3 or siR-
hoH cells in the presence or absence of IL3. In RhoH
overexpressing cells, however, stimulation with IL3
induces an increase in STAT1 tyrosine phosphorylation.
This finding was corroborated by performing a STAT1
immunoprecipitation and subsequent western blot ana-
lysis using a phospho-specific antibody (Figure 2B, left
panel). To assess the total levels of STAT1 the blot was
reprobed using a p84/p91 STAT1 antibody. The signal
intensities were quantified and normalised to STAT1
expression levels of control cells. The resulting quantifi-
cation shows that the phosphorylation levels of RhoH
cells for STAT1 are app. two-fold higher compared to
the control where no significant induction was detected
(Figure 2B, right panel).
Since STAT1 is known to mainly transduce apoptotic
or cycle arrest-inducing signals, we investigated whether
we could observe increased apoptosis in RhoH cells.
Apoptosis was induced in control cells, RhoH cells or
siRhoH cells through withdrawal of cytokine or treat-
ment with apoptosis inducing agents such as doxorubi-
cin or staurosporine. Apoptosis was then measured by
FACS analysis and subsequent quantification of
Annexin-V positive cells. However, no difference in the
susceptibility of RhoH cells was found compared to con-
trol cells (Figure 2C).
Overexpression of RhoH leads to the upregulation of
p21Cip1 and p27Kip1
We therefore reasoned that RhoH may play a role in
regulation of cell cycle progression, rather than apopto-
sis. The activities of cell cycle regulating cyclin depen-
dent kinases (CDKs) are negatively controlled by the
WAF/CIP family of CDK inhibitors. We examined the
expression levels of the cyclin-dependent kinase inhibi-
tors p21Cip1 which is known to be a STAT1-induced
gene [24] and p27Kip1 of the same family by quantitative
real-time PCR using GAPDH as a reference gene. Total
RNA was prepared from control cells and RhoH cells
and the gene expression of p21Cip1 and p27Kip1 were
determined (Figure 3A). RhoH cells showed a 55 and
40-fold increase in the expression of p21Cip1 and
p27Kip1, respectively, compared to control cells. There
were no significant changes in the expression of p21Cip1
and p27Kip1 detectable in siRhoH cells compared to the
control. This increased expression was also found in
IL3-treated bone marrow cells from wildtype compared
to RhoH deficient mice (data not shown). To corrobo-
rate this finding also on the protein level, we prepared
whole cell lysates from all three cell lines and subjected
them to western blot analysis using p21Cip1 and p27Kip1
specific antibodies and b-actin as a loading control (Fig-
ure 3B and 3C). Again, we found p21Cip1 and p27Kip1 to
be upregulated in cells overexpressing RhoH. The result-
ing quantification of the blots shows a statistically signif-
icant two-fold upregulation of p21Cip1expression. The
detected p27Kip1 expression is less prominent (1.3 fold)
but reproducible. We therefore propose that the expres-
sion of RhoH modulates IL3-induced proliferation
through upregulation of p21Cip1 and p27Kip1expression
and we suggest that this is a STAT1-dependent event.
Underexpression of RhoH enhances STAT5 activity
It was recently shown that reduced RhoH levels can be
connected to cancer and protection from apoptosis
[10,12,13]. STAT5 is the major STAT protein activated by
IL3 [25,26] and is described to induce anti-apoptotic genes
and cell proliferation. Consequently, dominant-negative
STAT5 leads to partial inhibition of IL3-induced prolifera-
tion [27]. We therefore examined the ability of RhoH or
siRhoH cells to activate STAT5 after IL3 stimulation.
Equal cell numbers of previously IL3-depleted BaF3 cells
were stimulated with 50 ng/ml IL3 and STAT5 was preci-
pitated from the resulting lysates. Western blot analysis
(Figure 4A, left panel) and quantification of pSTAT5 levels
(Figure 4A, right panel) that was corrected for the level of
total STAT5 showed a strong reduction of STAT5 tyro-
sine phosphorylation compared to control cells (50%).
This again corroborated our finding that proliferation in
response to IL3 is decreased in RhoH overexpressing cells.
Reduction of RhoH expression in siRhoH cells led to a
small increase (1.3-fold) in STAT5 tyrosine phosphoryla-
tion compared to control cells that showed higher varia-
tions between independent experiments. A possible
explanation for this observation is that parental BaF3 cells
have already comparatively low RhoH levels so that a
further decrease causes less prominent effects. As the
amount of precipitated total STAT5 showed some varia-
tion when same cell numbers were used (1x107/IP), we
additionally quantified STAT5 expression levels compar-
ing different pools of the transduced cell lines and using
20 μg of each lysate (Figure 4B) and did not find any dif-
ference (Figure 4B, right panel). Increased phosphorylation
of STAT5 in siRhoH cells was confirmed using intracellu-
lar staining by FACS analysis using a FITC-labelled
pSTAT5 antibody (Figure 4C).
IL3 Receptor a-chain expression is negatively regulated
by RhoH
The enhanced activation of STAT5 in cells that
expressed low levels of RhoH could potentially be
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caused by more efficient downstream signalling events
or by an increase in the expression of the ligand binding
cell surface receptor, IL3Ra (CD123). We therefore
determined the surface localisation of CD123 by FACS
analysis using a PE-labelled CD123 antibody. Figure 4D
shows that siRhoH cells express app. 25% more CD123
than control cells, while RhoH overexpressing cells
show a decrease of CD123 expression of app. 50% as
determined from three independent experiments.
Interestingly, it is known that a large number of AML
patients show elevated expression of CD123 and hyper-
activation of STAT5, which protects these cells from
Figure 3 RhoH upregulates p21Cip1 and p27Kip1 expression. (A) Quantification of p21Cip1 and p27Kip1 mRNA expression levels by quantitative
SYBR-green PCR in control cells, RhoH and siRhoH-transduced cells. Data were normalised to mRNA levels detected in control cells compared to
GAPDH. Statistical significance was analysed using the ‘s t-test (mean ± SD, n = 3; *P ≤ 0.05). (B, C) Whole cell lysates of control cells, siRhoH and
RhoH expressing cells were separated by 4-20% gradient SDS-PAGE and protein expression was detected by antibodies against p21Cip1 and
p27Kip1. Protein levels were normalised to b-actin expression (lower panel). Quantification and statistical significance were performed using the ‘s
t-test (mean ± SD, n = 2; *P ≤ 0.05).
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Figure 4 Low RhoH expression levels enhance STAT5 activity. (A) Control cells, siRhoH and RhoH expressing cells were starved for 3 h in
the absence of cytokine and FBS before stimulation with 50 ng/ml IL3. Cells were lysed and STAT5 was immunoprecipitated. Tyrosine
phosphorylated STAT5 and total STAT5 were detected by enhanced chemiluminescence using specific antibodies. Quantification of pSTAT5
levels was done after normalisation to total STAT5 levels in control cells and is presented as induction of phosphorylation compared to the
corresponding unstimulated sample. Statistical significance was analysed using the ‘s t-test (mean ± SD, n = 2; *P ≤ 0.05). (B) To verify equal
expression levels of STAT5 protein in all cell lines, STAT5 was detected from whole cell lysates and quantified after normalisation to b-actin levels
of control cells (mean ± SD, n = 3). (C) pSTAT5 levels were measured by intracellular FACS staining at 0 and 10 min of stimulation of previously
starved cells with 50 ng/ml IL3. Representative graphs from one out of three independently performed experiments are shown. (D) CD123
surface expression of control cells, siRhoH and RhoH cells determined by FACS analysis using a CD123-PE antibody. The left panel shows a
typical example and the right panel summarises the data of the mean fluorescence signal and the statistical analysis (mean ± SD, n = 3,
*P ≤ 0.05). (E) Quantification of IRF-1 mRNA expression levels of control cells and siRhoH-transduced cells was done by quantitative real-time PCR
using GAPDH as a reference gene. Data were normalised to the expression in control cells and are presented as fold induction of the IRF-1 gene
compared to control cells (mean ± SD, n = 3; *P ≤ 0.05).
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apoptosis [28]. It was found previously that the tran-
scription factor interferon regulatory factor-1 (IRF-1) is
highly overexpressed in AML eventually leading to the
upregulation of the IRF-1-dependent gene CD123 [29].
Since IRF-1 expression can be induced by STAT5 [30],
we checked whether we could detect an upregulation of
IRF-1 in siRhoH cells. Indeed, IRF-1 expression was app.
200 fold higher in siRhoH cells compared to control
cells (Figure 4E).
The acute monocytic leukaemia cell line THP-1 displays
an siRhoH phenotype
Low RhoH expression levels in samples from AML
patients represent an unfavourable prognostic factor
regarding patient survival. It was speculated that this
might be connected to an increased resistance of these
cells to apoptosis during chemotherapy through
increased Rac1 activity [13]. To investigate whether our
findings on the regulation of the anti-apoptotic factor
STAT5 through low RhoH expression levels might have
consequences in this scenario, we used THP-1 cells as a
model system. THP-1 cells are derived from a patient
with acute monocytic leukaemia. THP-1 cells correspond
to the M5 phenotype in the French-American-British
classification system of AMLs which were shown to have
low levels of RhoH [13]. As a control, we used THP-1
cells that had been transiently transfected with human
RhoH cDNA. Transfection efficiency was analysed by
western blot using an HA-antibody and b-actin as a load-
ing control (Figure 5A). When we investigated the sur-
face expression levels of CD123 we found CD123 to be
significantly downregulated in RhoH overexpressing cells
(50%). Again, this could be correlated with significant
changes in IRF-1 gene expression (Figure 5C) which
showed a 15-fold downregulation of RhoH overexpres-
sing cells compared to THP-1 cells. Therefore THP-1
cells show a phenotype similar to the one observed in
siRhoH BaF3 cells, with low RhoH levels and upregulated
IRF-1 and CD123 expression (5B and C).
Discussion
Previous work has shown that RhoH is a negative regu-
lator for growth, survival and cytoskeletal modifications
[14]. We show here that the expression level of RhoH
modulates the activity of STAT transcription factors
STAT5 and STAT1. In the IL3-dependent cell line
BaF3, RhoH acts as a specific negative regulator of IL3,
but not Epo-induced proliferation and silencing of RhoH
gene expression allows the cells to proliferate faster in
response to IL3.
The JAK-STAT pathway is a major signalling pathway
of haematopoietic cells that links proliferative signals to
the cell cycle machinery. In IL3-mediated signalling,
STAT5 plays a major role in the regulation of
proliferation, differentiation and anti-apoptotic signalling
[25,26]. We demonstrate that overexpression of RhoH
leads to a decrease in the activity of STAT5, whereas
silencing of RhoH expression causes an increased activ-
ity of STAT5 compared to control cells. No changes in
the expression level of total STAT5 protein were detect-
able and we therefore conclude that RhoH does not
modulate STAT5 activity through regulation of STAT5
expression levels. Most interestingly, we also could show
a link between RhoH expression levels and changes in
the surface expression of the ILR3 a-chain CD123.
It had previously been suggested that an elevated
CD123 expression, as it can be found in patients with
acute myeloid leukaemia (AML), may contribute to the
increased proliferation of leukaemic blasts, hyperactiva-
tion of STAT5 and poor prognosis [28]. Low expression
levels of RhoH were recently described as yet another
factor linked to poor patient prognosis [13]. Our data
now show that these two findings indeed might be con-
nected. Because low RhoH expression leads to an
increased STAT5 activity, STAT5 might then induce
expression of the IRF-1 gene, which in turn allows an
IRF-1-dependent upregulation of the CD123 gene, even-
tually leading to an increase in the surface levels of the
protein.
Although the regulatory influence of RhoH on STAT5
activity would be sufficient to account for the differ-
ences in proliferation, we observed an additional
mechanism by which RhoH negatively regulates IL3-
induced growth, namely the activation of STAT1 in
RhoH overexpressing cells. STAT1 is the key factor that
transduces the antiproliferative effects of interferons
[31] and activation of STAT1 coincides with cell cycle
arrest or apoptosis. As a consequence, STAT1 knock-
out mice develop tumours more rapidly [32,33]. When
we screened control cells and RhoH overexpressing cells
for differences in their sensitivity towards apoptotic sti-
muli, we were not able to find any. However, siRhoH
showed increased survival after cytokine deprivation and
readdition of IL3 to starved cells induced a pool of
rapidly growing cells, whereas parental cells did not
recover (unpublished data).
It has been reported that STAT1 activation can lead
to the upregulation of p21Cip1 causing subsequent cell
cycle arrest or apoptosis and a STAT1 DNA binding
site was found in the p21Cip1 promoter [24]. Another
member of this family, p27Kip1, was shown to be down-
regulated by IL3 and BCR-ABL [34]. Interestingly, we
found that p21Cip1 and p27Kip1 are both upregulated
when RhoH is expressed, i.e. STAT1 is activated, and
we suggest this as a RhoH-dependent mechanism that
serves to regulate progression in the cell cycle. We pro-
pose a model, where the balance between proliferation
and apoptosis is fine-tuned by the expression level of
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RhoH. While high levels of RhoH lead to increased
STAT1 but reduced STAT5 activity, downregulation of
RhoH expression activates STAT5-dependent prolifera-
tion and survival signals. It will be important to examine
whether in IL3 sensitive, differentiating haematopoietic
progenitor cells, the expression level of RhoH can regu-
late the balance between proliferation and cell cycle
arrest or apoptosis. There was no obvious haematopoie-
tic defect in RhoH-deficient animals, however, it is pos-
sible that the disturbed IL3-dependent signalling can be
Figure 5 The AML cell line THP-1 displays an siRhoH phenotype. (A) THP-1 cells were either transfected with HA-RhoH or the empty vector,
lysed and separated by SDS-PAGE. Detection of HA-RhoH was performed with an HA-specific antibody and enhanced chemiluminescence. As a
loading control, the expression of b-actin was detected. (B) THP-1 cells transfected with HA-RhoH or the empty vector were analysed for CD123
expression by FACS using a CD123-APC antibody. Data are presented as percentage of the mean fluorescence signal for CD123 (mean ± SD, n =
3, *P ≤ 0.05). (C) IRF-1 mRNA expression is decreased in RhoH over-expressing THP-1 cells. Quantification of IRF-1 mRNA expression levels by
quantitative SYBR-green PCR in control cells and RhoH-transfected THP-1 cells using human IRF-1 specific primers and GAPDH as a reference
gene. Data were normalised to the expression in control cells and are presented as fold induction (mean ± SD, n = 3; ***P ≤ 0.005).
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compensated by other cytokines. In addition, it is known
that in B cells, RhoH is a target of somatic hypermuta-
tion and translocation which affects the expression of
the protein [10]. Nevertheless, RhoH-deficient animals
did not develop lymphomas or show other B cell malig-
nancies, which is a discrepancy that shows the limit of
the animal model.
Two recent publications now link low RhoH protein
levels to cancer [12,13]. In AML, RhoH expression is
low, causing high levels of active, GTP-bound Rac1 and
eventually resistance to chemotherapeutic apoptosis
[13]. Our results indicate that other signalling pathways,
such as STAT5 activation and high expression of the
IL3-binding a chain, might additionally be modulated
by RhoH and contribute to the disease. To understand
the importance of RhoH for the development of haema-
topoietic malignancies, it will be crucial to establish a
link between RhoH mutations, its expression on the pro-
tein level and the activity of signalling molecules such as
STATs that are known to be upregulated in a number
of myeloproliferative disorders [35,36]. In addition, the
JAK-STAT pathway plays a central role in cytokine-
mediated signalling in haematopoiesis and the immune
system. This pathway has not yet been discussed as a
potential target of RhoH and it will therefore be inter-
esting to see whether cytokine receptors other than IL3
are regulated through the expression level of RhoH.
Conclusions
Taken together, we show that the haematopoietic
GTPase RhoH can modulate signalling through the
JAK-STAT pathway. High levels of RhoH lead to prefer-
ential activation of STAT1 and reduced cell prolifera-
tion. While there were no changes in apoptosis
detectable at high RhoH levels, we found a pronounced
upregulation of p21Cip1 and p27Kip, two genes involved
in cell cycle arrest. Low RhoH levels led to an upregula-
tion of IL3-dependent cell growth, STAT5 activity and
an upregulation of CD123 surface expression. This phe-
notype was also found in human monocytic THP-1
cells, suggesting that a correction of low RhoH expres-
sion levels might be beneficial for AML patients.
Methods
Materials
Stimulation with IL3 was performed with recombinant
IL3 (Natutec, Frankfurt, Germany). BaF3 cells were
obtained from DSMZ (Braunschweig, Germany). All
data shown were performed at least in three indepen-
dent experiments.
cDNAs cloning and sequencing
The puromycin resistance cassette was amplified by PCR
from the vector pSilencer 5.1 U6 retro (Ambion, Austin,
USA) and restriction sites for Sal-I and Xho-I were
introduced. Sense primer puromycin resistance: 5′-GCT
AAC GTC GAC CGG GTA GGG GAG GCG CT-3′;
anti sense primer puromycin resistance: 5′-GCT AAT
CTC GAG TCA GGC ACC GGG CTT GC-3′. The PCR
product was cloned into the Sal-I restriction site of the
pMX-IRES-CD4 vector [23]. The resulting construct
(pMX-IRES-CD4-Puro) was verified by sequence analy-
sis. Full length murine RhoH was cloned into BamH-I
and Not-I sites of the pMX-IRES-CD4-Puro vector. The
resulting construct pMX-RhoH-IRES-CD4-Puro RhoH
was verified by sequence analysis.
Cell culture reagents
BaF3 cells were maintained in RPMI1640 medium con-
taining 10% FBS, 1% Pen/Strep and IL3 containing
supernatant (0.5%) generated by the cell line X63Ag8-
653 [37]. THP-1 cells were cultivated in RPMI1640
medium containing 10% FBS and 1% Pen/Strep.
Retroviral vector transduction
Retroviral supernatants were generated and used to
transduce the IL3-dependent pro-B cell line BaF3 as
described [38]. Briefly, six-well plates of 293-derived
Phoenix eco cells were transiently transfected with
cDNAs encoding for murine RhoH gene (pMX-IRES-
CD4-Puro) or the empty vector (control). After 48 h,
750 μl of viral supernatant was added to 5×105 BaF3
cells and centrifuged for 120 min at 37 °C and 900 g in
the presence of 16 μg of Polybrene (Sigma, Taufkirchen,
Germany). Transduced cells were selected in the pre-
sence of 1.5 μg/ml puromycin and transfection efficiency
was evaluated by FACS analysis of human CD4 expres-
sion (BD Biosciences, Germany). To generate siRNAs
specific to mouse RhoH a silencing 21mer as described
in [14] was cloned into the vector pSilencer 5.1 U6
(Ambion, Austin, USA). As a control, a scrambled
sequence with no similarity to a mouse gene was used.
After infection, transduced cells were selected in the
presence of 1.5 μg/ml puromycin.
Transient transfections
THP-1 cells were transiently transfected with the human
HA-tagged RhoH cDNA containing vector pMX-IRES-
GFP or the corresponding empty vector using Metafec-
tene (Biontex, Martinsried, Germany) according to man-
ufacturer’s instructions.
FACS analysis
For the intracellular analysis of phosphorylated STATs,
cells were fixed with 4% PFA/PBS prior to overnight
permeabilization with methanol. Phosphorylated STATs
were detected using FITC-labelled pSTAT1 (Y701),
pSTAT5 (Y694) antibodies or the respective isotype
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controls (BD Bioscience, Heidelberg, Germany). For the
analysis of CD123 surface expression, cells were incu-
bated for 45 min with PBS/2% FBS before labelling with
murine CD123-PE or human CD123-APC antibodies
(eBioscience, Frankfurt a.M, Germany), or the respective
isotype controls (BD Biosciences, Heidelberg, Germany).
Cells were analyzed on a FACS Canto (BD Biosciences,
Heidelberg, Germany).
Measurement of Cell Viability
Cytokine-dependent growth was determined by quantifi-
cation of cellular ATP using the Cell Titer Glo Assay
(Promega, Madison, WI, USA). Cells were washed with
RPMI and starved for 3 hours in the presence of 1 mg/
ml BSA. 3.75 × 104 cells/ml were seeded in a 96 well
plate with the corresponding cytokine concentrations.
Cells were processed according to the manufacturer’s
protocol and luminescence was determined using a
Lumistar Optima luminometer (BMG Labtech, Offen-
burg, Germany).
Annexin V Assay
Cells were depleted of IL3 for 3 hours and 2.5 × 105
BaF3 cells/ml were seeded in a 6-well plate. Cells were
either incubated overnight in regular BaF3 cell medium,
in the absence of IL3 or under other stress conditions,
such as treatment with 1 μM doxorubicin or 1 μM
staurosporine (Sigma, Taufkirchen, Germany). Cells
were stained with Annexin-V and propidium iodide
according to the Annexin-V-FLUOS kit protocol pro-
vided by the manufacturer (Roche, Penzberg, Germany).
Apoptosis was quantified using a FACS Canto (BD Bios-
ciences, Heidelberg, Germany).
Whole Cell Extracts and Immunoprecipitation
BaF3 cells were starved for 3 h without IL3 and FBS
before stimulation of 1 × 107 cells with 50 ng/ml IL3.
Cells were lysed in NP40 lysis buffer with protease and
phosphatase inhibitors (Roche, Penzberg, Germany) and
incubated for 45 min at 4°C. After centrifugation, lysates
were immunoprecipitated overnight with 5 μl of STAT1
or STAT5 antibodies (Santa Cruz Biotechnology, Santa
Cruz, USA) bound to Protein A/G Sepharose (Santa
Cruz Biotechnology, Santa Cruz, USA). Samples were
separated by 12% SDS-PAGE, transferred to nitrocellu-
lose and incubated with the corresponding phospho-spe-
cific antibodies for STAT1 (701) or STAT5 (Y694) (Cell
Signaling Technology, Danvers MA, USA) or total
STAT1/STAT5, followed by incubation with HRP-
coupled anti-rabbit antibody (Cell Signaling Technology,
Danvers MA, USA) and detection by enhanced
chemiluminescence.
Detection of proteins after western blotting of whole
cell lysates (20 μg protein) was performed using
antibodies directed against b-actin and p27Kip1 (Cell Sig-
naling Technology, Danvers MA, USA), p21Cip1, STAT5
or HA-tag (Santa Cruz Biotechnology, Santa Cruz,
USA). Quantification of immunoblots was performed
using the Image Analysis System Bioprofil (Fröbel, Ger-
many) Bio ID software version v12.06. Signal intensity
was calculated against the loading control and is pre-
sented as fold induction compared with the unstimu-
lated control or cells transduced with the empty vector
(mean ± SD; n ≥ 2). Statistical significance was assessed
by using a paired ‘s t-test, with *P < 0.05, **P < 0.01 and
***P < 0.005.
Quantitative real-time PCR
Small-scale preparations of RNA were made from 1 ×
106 cells using the High Pure RNA Isolation Kit (Roche,
Penzberg, Germany). Total RNA was transcribed with
First Strand cDNA Kit (Fermentas GmbH, St. Leon-Rot,
Germany). Aliquots of the cDNA were used for quanti-
tative PCR analysis using the 7900 HT Fast Real-Time
PCR System (Applied Biosystems, Darmstadt, Germany)
and the ABsolute QPCR SYBR Green Rox Mix (Abgene,
Epson, UK). The following primers were used: murine
gapdh sense 5′-TTC ACC ACC ATG GAG AAG GC-3′
and antisense 5′-GGC ATG GAC TGT GGT CAT GA-
3′, human gapdh sense 5′-ACG GAT TTG GTC GTA
TTG GGC-3′ and antisense 5′-TTG ACG GTG CCA
TGG AAT TTG-3′, murine RhoH sense 5′-GCT ACT
CTG TGG CCA ACC AT-3′ and antisense 5′-AGG
TCC CAC CTC TCT CTG GT-3′, p27 sense 5′-AGG
GCC AAC AGA ACA GAA GA-3′ and antisense 5′-
CTC CTG GCA GGC AAC TAA TC-3′and p21 sense
5′-GCA GAC CAG CCT GAC-3′ and antisense 5′-GCA
GGC AGC GTA TAT ACA GGA-3′, murine IRF-1
sense 5′-GGA GAT GTT AGC CGG ACA CT-3′, mur-
ine IRF-1 antisense 5′-TGC TGA CGA CAC ACG GTG
A-3′, human IRF-1 sense 5′-GCT GGA CAT CAA CAA
AGG AT-3′ and antisense 5′-TGG TCT TTC ACC
TCC TCG AT-3′. Results were analyzed using the
Abgene software. For further analysis, results were
exported to Excel (Microsoft) and calculated by relative
ddCt method. All results were normalised with respect
to the reference gene GAPDH. Results were then nor-
malised to control cells (mean ± SD; n≥2). Statistical
significance was assessed using a paired ‘s t-test, with
*P < 0.05, **P < 0.01 or with ***P < 0.005.
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